GlassScriptPhysician profile
Kemp W Bundy
NPI 1396797940
$8,425.96
in general payments reported to CMS, 2019-2025
9 companies · $60.17 in 2025
The $60.17 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,366 · 2021: $1,401 · 2022: $105 · 2023: $2,062 · 2024: $432 · 2025: $60.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,649 · Food and Beverage: $905.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,648.50 |
| Food and Beverage | $905.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $4,241.83 | 2019-2024 | Arexvy, Nucala |
| Genzyme Corporation | $1,816.13 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,648.50 | 2023 | Dupixent |
| Genentech USA, INC. | $260.31 | 2019-2024 | Xolair |
| Shire North American Group INC | $200.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $121.84 | 2024 | Fasenra |
| Csl Behring | $61.97 | 2019-2023 | Kcentra, Haegarda |
| Novartis Pharmaceuticals Corporation | $52.37 | 2024-2025 | |
| Galderma Laboratories, L.P. | $23.01 | 2025 | Nemluvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kemp Bundy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.